Cargando…

Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma

BACKGROUND: The incidence of cutaneous melanoma (CM) is increasing, and its prognosis is not optimistic. Although immune checkpoint (ICP) inhibitors are effective in the treatment of CM patients, they are not effective for all CM patients. There is an urgent need for a marker to predict both the pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Rui, Yang, Fan, Zhang, Tongtong, Li, Ji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738081/ https://www.ncbi.nlm.nih.gov/pubmed/35003069 http://dx.doi.org/10.3389/fimmu.2021.756282

Ejemplares similares

Clinical significance and immune landscape of KIR2DL4 and the senescence‐based signature in cutaneous melanoma
por: Mao, Rui, et al.
Publicado: (2022)

Evidence for a causal relationship between psoriasis and cutaneous melanoma: a bidirectional two-sample Mendelian randomized study
por: Zhao, Nana, et al.
Publicado: (2023)

Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy
por: Lv, Xiaohui, et al.
Publicado: (2022)

Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma
por: Zhu, Zheng, et al.
Publicado: (2022)

Identification of fatty acid metabolism–related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma
por: Xu, Yujian, et al.
Publicado: (2022)

Cutaneous manifestations associated with immune checkpoint inhibitors
por: Watanabe, Tomoya, et al.
Publicado: (2023)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer
por: Xie, Xiaoxue, et al.
Publicado: (2020)

Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma
por: Liu, Da, et al.
Publicado: (2023)

The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade
por: Park, Jang Hyun, et al.
Publicado: (2022)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma
por: Yan, Junya, et al.
Publicado: (2022)

Immune-related risk score: An immune-cell-pair-based prognostic model for cutaneous melanoma
por: Li, Mingjia, et al.
Publicado: (2023)

The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma
por: Issam Salah, Nour el Imane, et al.
Publicado: (2023)

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
por: Xu, Yufei, et al.
Publicado: (2022)

Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
por: Elia, Angela Rita, et al.
Publicado: (2018)

Diversity of immune checkpoints in cancer immunotherapy
por: Guo, Zhangyan, et al.
Publicado: (2023)

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
por: Buder-Bakhaya, Kristina, et al.
Publicado: (2018)

Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma
por: Fan, Tao, et al.
Publicado: (2021)

Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma
por: Zhang, Wengang, et al.
Publicado: (2022)

Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation
por: Dumolard, Lucile, et al.
Publicado: (2023)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
por: Wang, Xueyan, et al.
Publicado: (2022)

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
por: Liu, Tracy W, et al.
Publicado: (2023)

B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade
por: Singh, Shubhra, et al.
Publicado: (2022)

On the clinical significance of cutaneous melanoma's precursors
por: Noto, Giuseppe
Publicado: (2012)

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
por: Lim, Su Yin, et al.
Publicado: (2023)

CEBPB is associated with active tumor immune environment and favorable prognosis of metastatic skin cutaneous melanoma
por: Yang, Jingrun, et al.
Publicado: (2022)

Correlation Between Tumor-Associated Macrophage and Immune Checkpoint Molecule Expression and Its Prognostic Significance in Cutaneous Melanoma
por: Kim, Young Jae, et al.
Publicado: (2020)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma
por: Kang, Kai, et al.
Publicado: (2020)

Tumor Apolipoprotein E is a key checkpoint blocking anti-tumor immunity in mouse melanoma
por: Wu, Xiaofang, et al.
Publicado: (2022)

Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma
por: Sun, Steven H., et al.
Publicado: (2021)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
por: Khair, Duaa O., et al.
Publicado: (2019)

Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
por: Loo, Kimberly, et al.
Publicado: (2022)

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
por: Petrova, Vera, et al.
Publicado: (2023)

Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
por: Cao, Ting, et al.
Publicado: (2023)

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy
por: Pickering, Chad, et al.
Publicado: (2023)

Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts
por: Gao, Zixu, et al.
Publicado: (2022)

A Novel Signature of 23 Immunity-Related Gene Pairs Is Prognostic of Cutaneous Melanoma
por: Xue, Ya-Nan, et al.
Publicado: (2020)

Significance of immunogenic cell death-related genes in prognosis prediction and immune microenvironment landscape of patients with cutaneous melanoma
por: Fu, Weijiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u5e1ear24h1u3qkvvi9abtin1u